Controversies surrounding estrogen use in postmenopausal women

Annals of Pharmacotherapy

Volumn 31, Issue 6, 1997, Pages 745-755

  Witt, Daniel M ^a   Lousberg, Tammy R ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Estrogen; Menopause

Indexed keywords

ESTROGEN;

BREAST CANCER; CANCER RISK; ESTROGEN THERAPY; FEMALE; HUMAN; INFORMED CONSENT; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0030917577     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100615     Document Type: Review

References (55)

1. Andrews WC. The transitional years and beyond. Obstet Gynecol 1995; 85:1-5.
2. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-4.
3. Utian WH, Schiff I. North American Menopause Society - Gallup survey on women's knowledge, information, sources and attitudes to menopause and hormone replacement therapy. Menopause 1994;1:39-48.
4. Tang M, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
5. Moore AO, Mullins PM, Pugh MC. Hormonal replacement therapy. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Matzke GR, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 2nd ed. East Norwalk, CT: Appleton & Lange, 1993:1241-50.
6. Laurtizen C. Clinical use of oestrogens and progestogens. Maturitas 1990;12:199-214.
7. Oldenhave A, Netelenbos C. Pathogenesis of climacteric complaints: ready for the change. Lancet 1994;343:649-53.
8. te Velde ER, van Leusden HAIM. Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease. Lancet 1994;343:654-8.
9. Iosif CS, Batra S, Anders EK, Astedt B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 1981;141:817-20.
10. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
11. Chow MSS. Benefit/risk of estrogen therapy in cardiovascular disease: current knowledge and future challenges. J Clin Pharmacol 1995;35 (suppl):11S-7S.
12. Healy B. PEPI in perspective; good answers spawn pressing questions (editorial). JAMA 1995;273:240-1.
13. Whitehead M, Godfree V. Risks and contraindications. In: Whitehead M, Godfree V, eds. Hormone replacement therapy: your questions answered. New York: Churchill Livingstone, 1992:135,139-41,143.
14. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328: 1069-75.
15. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
16. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willen WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
17. Whitehead M, Godfree V. Benefits of HRT. In: Whitehead M, Godfree V, eds. Hormone replacement therapy: your questions answered. New York: Churchill Livingstone, 1992:62.
18. Martin KA, Freeman MW. Postmenopausal hormone replacement therapy (editorial). N Engl J Med 1993;328:1115-7.
19. Sagraves R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharmacol 1995;35(suppl):2S-10S.
20. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy: a 10-year prospective study in the relationship of osteoporosis. Obstet Gynecol 1979;53:277-81.
21. Weiss NS, Ure CI, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
22. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
23. Ettinger B, Grady D. Maximizing the benefit of estrogen therapy for prevention of osteoporosis. Menopause 1994;1:19-24.
24. Corson SL. A practical guide to prescribing estrogen replacement therapy. Int J Fertil 1995;40:229-47.
25. Mazess RB, Barden H, Ettinger M, Schultz E. Bone density of the radius, spine, and proximal femur in osteoporosis. J Bone Miner Res 1988; 3:13-8.
26. Erwin WG. Geriatrics. In: DiPiro JT, Talbcrt RL, Hayes PE, Yee GC, Matzke GR, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 2nd ed. East Norwalk, CT: Appleton & Lange, 1993:64-70.
27. Toran-Allerand CD, Miranda RC, Bentham WD, Sohrabji F, Brown TJ, Hochberg RB, et al. Estrogen receptors colocalize with low affinity nerve growth factor receptors in cholinergic neurons of the basal fore-brain. Proc Natl Acad Sci U S A 1992;89:4668-72.
28. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging 1994; 15 (suppl):S195-7.
29. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer's amyloid beta precursor protein. J Biol Chem 1994;269:13065-8.
30. Honjo H, Tanaka K, Kashiwagi T, Urabe M, Okada H, Hayashi M, et al. Senile dementia - Alzheimer's type and estrogen. Horm Metab Res 1995;27:204-7.
31. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61.
32. Graves AB, White E, Koepsell TD, Reifler BV, van Belle G, Larson EB, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28: 766-74.
33. Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140:262-7.
34. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995;87:1067-70.
35. Herrinton L, Weiss N. Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 1993;3:308-18.
36. Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 1985;65:441-6.
37. Whitehead MI, Fraser D. Controversies concerning the safety of estrogen replacement therapy. Am J Obstet Gynecol 1987;156:1313-22.
38. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy II, neoplasia. Am J Obstet Gynecol 1979;133:537-47.
39. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-23.
40. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 117:1038-41.
41. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
42. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274: 137-42.
43. Cyr MG, Nachtigall LE, Andrews WC, Wren BG, Bush TL, Speroff L, et al. Demystifying the hormone/breast cancer connection. Women's Health Digest 1995;1:197-202.
44. Adami HO, Persson I. Hormone replacement and breast cancer: a remaining controversy (editorial). JAMA 1995;274:178-9.
45. Salva K. Colorectal cancer. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Matzke GR, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 2nd ed. East Norwalk, CT: Appleton & Lange, 1993:1958.
46. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
47. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
48. Perez-Gutthann S, Garcia-Rodriguez LA, Castellsague J, Duque-Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997;314:796-800.
49. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511-8.
50. Whitehead M, Godfree V. Types of HRT available. In: Whitehead M, Godfree V, eds. Hormone replacement therapy: your questions answered. New York: Churchill Livingstone, 1992:97-110.
51. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(suppl):18S-24S.
52. Andrews WC. Continuous combined estrogen/progestin hormone replacement therapy. P&T 1995;20(suppl):1-11.
53. Grady D, Gobretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
54. Archer DF, Pickar JH, Bottiglione F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-92.
55. Whitehead M, Godfree V. Duration of therapy. In: Whitehead M, Godfree V, eds. Hormone replacement therapy: your questions answered. New York: Churchill Livingstone, 1992:197-9,203.